Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A plus escitalopram vs placebo plus escitalopram in adults with major depressive disorder
2006-004146-16Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing SR58611A + escitalopram with Placebo + escitalopram (2 arms). Primary endpoint: Change in 17-item HAM-D total score from baseline to week 8. Started Nov 2006; status: completed.
02
Drugs
amibegron
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-004146-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004146-16.